Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Clearside Biomedical, Inc. (NASDAQ: CLSD).

Full DD Report for CLSD

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLSD)

Clearside Biomedical to Present at the 2018 UBS Global Health Care Conference
ALPHARETTA, Ga., May 16, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. W...
Source: GlobeNewswire
Date: May, 16 2018 16:30
Clearside Biomedica's (CLSD) CEO Daniel White on Q1 2018 Results - Earnings Call Transcript
Clearside Biomedical, Inc. (CLSD) Q1 2018 Earnings Conference Call May 9, 2018 08:30 AM ET Executives Stephen Kilmer - Investor Relations Daniel White - Chief Executive Officer Glen Noronha - Chief Scientific Officer Charlie Deignan - Chief Financial Officer Brion Raymond - C...
Source: SeekingAlpha
Date: May, 12 2018 04:49
Clearside Biomedical EPS of -$0.62
Clearside Biomedical (NASDAQ: CLSD ): Q1 EPS of -$0.62 misses by $0.04 . Cash, cash equivalents and short-term investments of $101.5M Press Release More news on: Clearside Biomedical, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 09 2018 07:04
Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update
ALPHARETTA, Ga., May 09, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported financial results for the quarter ended March 31, 2018, ...
Source: GlobeNewswire
Date: May, 09 2018 07:00
Clearside Biomedical to Report First Quarter 2018 Financial Results on May 9, 2018 - Conference Call to Follow
ALPHARETTA, Ga., May 02, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today announced today that its first quarter 2018 financial resul...
Source: GlobeNewswire
Date: May, 02 2018 16:30
Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials
By Slingshot Insights intern Samuel Jordan We have a full slate of exciting Phase 2 data releases for Q2 2018. This article will focus on four that we think are going to be major catalysts for the companies involved. The Phase 2 data addressed in this article come from trials for Sangamo...
Source: SeekingAlpha
Date: April, 19 2018 12:04
Week 15 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 15: Market conditions continue with extreme volatility. The positive momentum gauge remains strongly in the red zone, declining very slightly this past week from a value of 16 to a value of 14, but still in low probability range of positive momentum...
Source: SeekingAlpha
Date: April, 08 2018 05:31
Recent Analysis Shows Clearside Biomedical, tronc, Stifel Financial, Woodward, WisdomTree Investments, and Aluminum Corporation of China Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearside Biomedical, Inc. (NASDAQ:CLSD), tronc, Inc. (NASDAQ:TRNC), Sti...
Source: GlobeNewswire
Date: April, 05 2018 08:10
Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select...
Source: SeekingAlpha
Date: March, 31 2018 09:55
Week 13 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 13: Market conditions continue with extreme volatility. My momentum gauge dropped throughout the past week to a value of 23 down significantly from the prior week at a value of 38. Volatility in the market remains at high levels and we have not been...
Source: SeekingAlpha
Date: March, 24 2018 23:13

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-06-2010.6610.7410.9610.6029387,708
2018-06-1910.5010.6110.69910.45344,864
2018-06-1810.6810.5910.8910.45346,698
2018-06-1510.4510.7010.7210.38504,264
2018-06-1410.1110.4910.5510.04427,515

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-2181,849239,90034.1180Cover
2018-06-2010,686110,8839.6372Cover
2018-06-1926,72292,69128.8291Cover
2018-06-1843,60985,34151.0997Short
2018-06-1574,027109,18367.8008Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLSD.


About Clearside Biomedical, Inc. (NASDAQ: CLSD)

Logo for Clearside Biomedical, Inc. (NASDAQ: CLSD)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $371,787,766 - 05/11/2018
  • Issue and Outstanding: 31,913,113 - 03/12/2018

 


Recent Filings from (NASDAQ: CLSD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018

 

 


Daily Technical Chart for (NASDAQ: CLSD)

Daily Technical Chart for (NASDAQ: CLSD)


Stay tuned for daily updates and more on (NASDAQ: CLSD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLSD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLSD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of CLSD and does not buy, sell, or trade any shares of CLSD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/